H&R Achieves Substantial Growth in Q1 2024

H&R GmbH & Co. KGaA reported a strong start to the year, with first quarter earnings significantly surpassing results from the same period last year. The chemical company posted an EBITDA of EUR 21.3 million for Q1 2024, a sharp increase from EUR 14.3 million in Q1 2023. However, sales revenues fell to EUR 337.0 million, down from EUR 349.0 million in the previous year.

The company’s quarterly financial statement revealed positive growth across various segments. The ChemPharm Refining and ChemPharm Sales segments experienced notable improvements in EBITDA, increasing to EUR 10.5 million and EUR 10.9 million respectively. Despite these gains, challenges included a decline in operating cash flow and free cash flow compared to the previous year.

H&R credits these results to a combination of strategic initiatives and lower raw material prices. The detailed quarterly statement is available in the "Investor Relations" section of their website.